These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Measles, mumps, rubella vaccine and allergy to egg. Lang S Am Fam Physician; 1998 Sep; 58(4):863-4. PubMed ID: 9767722 [No Abstract] [Full Text] [Related]
5. Combined trivalent and bivalent measles, mumps and rubella virus vaccination. A controlled trial. Swartz TA; Klingberg W; Klingberg MA Infection; 1974; 2(3):115-7. PubMed ID: 4606362 [No Abstract] [Full Text] [Related]
6. [Conjugated vaccine against measles, rubella and mumps]. Vopr Virusol; 1989; 34(1):117-9. PubMed ID: 2728403 [No Abstract] [Full Text] [Related]
7. Recommendations for using MMR vaccine in children allergic to eggs. Khakoo GA; Lack G BMJ; 2000 Apr; 320(7239):929-32. PubMed ID: 10787255 [No Abstract] [Full Text] [Related]
8. Egg hypersensitivity and measles-mumps-rubella vaccine administration. Beck SA; Williams LW; Shirrell MA; Burks AW Pediatrics; 1991 Nov; 88(5):913-7. PubMed ID: 1945631 [TBL] [Abstract][Full Text] [Related]
9. Revaccination against measles and rubella. Cutts FT BMJ; 1996 Mar; 312(7031):589-90. PubMed ID: 8595319 [No Abstract] [Full Text] [Related]
10. Administration of measles-mumps-rubella vaccination with other childhood schedule vaccines. Heath TC; Burgess MA; O'Brien ED Commun Dis Intell; 1998 Aug; 22(8):159. PubMed ID: 9735551 [No Abstract] [Full Text] [Related]
11. Safe administration of the measles vaccine to children allergic to eggs. James JM; Burks AW; Roberson PK; Sampson HA N Engl J Med; 1995 May; 332(19):1262-6. PubMed ID: 7708070 [TBL] [Abstract][Full Text] [Related]
12. A field trial of combined measles-mumps-rubella vaccine. Satisfactory immunization with 188 children in Chile. Borgoño JM; Greiber R; Solari G; Concha F; Carrillo B; Hilleman MR Clin Pediatr (Phila); 1973 Mar; 12(3):170-2. PubMed ID: 4701464 [No Abstract] [Full Text] [Related]
13. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. Peltola H; Heinonen OP; Valle M; Paunio M; Virtanen M; Karanko V; Cantell K N Engl J Med; 1994 Nov; 331(21):1397-402. PubMed ID: 7969278 [TBL] [Abstract][Full Text] [Related]
14. Clinical trial of a new trivalent measles-mumps-rubella vaccine in young children. Vesikari T; Ala-Laurila EL; Heikkinen A; Terho A; D'Hondt E; André FE Am J Dis Child; 1984 Sep; 138(9):843-7. PubMed ID: 6383020 [TBL] [Abstract][Full Text] [Related]
15. [Vaccination rate for triple measles-rubella-mumps vaccine in Empoli Val d'Elsa area health district U.S.L. 11, Tuscany Region]. Salvadori P Ann Ig; 1998; 10(1):19-24. PubMed ID: 9616974 [No Abstract] [Full Text] [Related]
16. Evaluation of a trivalent measles, mumps, rubella vaccine in children. Bloom JL; Schiff GM; Graubarth H; Lipp RW; Jackson JE; Osborn RL; Kenny MT J Pediatr; 1975 Jul; 87(1):85-7. PubMed ID: 1151553 [No Abstract] [Full Text] [Related]
17. [Morbidity, vaccine coverage and immunity against measles, mumps and rubella in a Gallician population from 2 to 5 years old]. Vázquez Fernández E; López Rois F; Vázquez Carrete JA; Gómez Tato B; Alvarez Ares M An Esp Pediatr; 1987 Jul; 27(1):27-31. PubMed ID: 3662251 [TBL] [Abstract][Full Text] [Related]
18. MMR vaccine coverage at 24 months stabilises in the UK. Commun Dis Rep CDR Wkly; 1999 Mar; 9(13):113, 116. PubMed ID: 10230112 [No Abstract] [Full Text] [Related]